Posted by Michael Wonder on 06 Nov 2020
New drug for gastro-intestinal stromal tumours to be launched in Australia, New Zealand and South East Asia following distribution agreement
5 November 2020 - Qinlock is already approved by the TGA and US FDA.
A new therapy to treat advanced gastro-intestinal stromal tumours will be available to patients in Australia, New Zealand and in some parts of South East Asia, following an exclusive distribution agreement.
